Daewoong Pharmaceutical Enters CDMO... Obtains License for Advanced Biopharmaceutical Manufacturing
[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 14th that it has obtained a manufacturing license for advanced biopharmaceuticals from the Ministry of Food and Drug Safety and will enter the contract development and manufacturing organization (CDMO) business.
Based on this license, Daewoong Pharmaceutical will start an "all-in-one package" business encompassing manufacturing of advanced biopharmaceuticals including cell therapy products, development, quality testing, regulatory support, storage and delivery, and sales.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company plans to provide its cell therapy production technology, pharmaceutical sales, and marketing services that meet global standards to partner companies under cooperation agreements.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
